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1. Introduction  
Rapidly progressive glomerulonephritis (RPGN) is one of the nephrology emergencies 
which needs special attention. RPGN is a clinical description which determines by 
symptoms and signs of glomerulonephritis (GN); edema, hypertension and gross 
hematuria, and evidence of acute renal failure(severe decrease in glomerular filtration rate 
presents as oliguria or anuria, and increased serum levels of BUN and creatinine). Definite 
diagnosis of the disorder is based on kidney biopsy's findings. Early diagnosis and 
appropriate treatment plays a critical role in renal saving and preventing permanent 
glomerular damage. 
This chapter will focus on clinical manifestations, therapeutic protocols and prognostic 
factors in patients with different subtypes of RPGN. 
Rapidly progressive glomerulonephritis (RPGN) is defined as a syndrome with abrupt or 
insidious onset of hematuria, proteinuria, anemia, and rapidly progressing acute renal 
failure(ARF), and special findings on light microscopy examination of kidney biopsy's 
specimen; crescentic lesions which usually involved most glomerular architectures 
(Hirayama, et al., 2008; Rutgersetal., 2004). It also characterized by rapid loss of renal 
function (GFR<50% within 3 months)with histological findings of crescent lesions which 
usually involves>50 % of glomeruli (Couser, 1988). 
RPGN can be primary or secondary. Secondary forms occur in any form of severe 
glomerulonephritis including membranoproliferative GN, IgA nephropathy, post infectious 
GN, and systemic lupus erythematous (SLE). Primary RPGN is an autoimmune disease 
which is divided into three immunopathologic categories:(Rutgerset al., 2004; Haas .& 
Eustace, 2004): 
Type 1 RPGN: glomerulonephritis with antibodies directed against the glomerular basement 
membrane (GBM) (anti -GBM mediated GN) 
Type II RPGN: immune-complex induced glomerulonephritis 
Type III RPGN: Antineutrophil cytoplasmic antibody associated glomerulonephritis 
(ANCA-associated glomerulonephritis or pauci-immune GN) 
RPGN type 1 and 2 are responsible for 10 -20 %  and 40 %  of all cases respectively. RPGN 
type 2 can be found in different forms of systemic disease such as post infectious 
GN(PSGN), Ig-A nephropathy, Henoch–Schönlein purpura (HSP), SLE, membranous 
GN(MGN) or membrano- proliferative GN(MPGN). A few cases of idiopathic immune -
complex-mediated RPGN have been reported (Jindal, 1999). 
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Interestingly different forms of RPGN share similar clinical features including hematuria, 
proteinuria, edema, hypertension and symptoms of ARF .patients with Anti –GBM anti - 
body or pauci-immune RPGN (ANCA -associated vasculitis) may have pulmonary 
hemorrhage and hemoptysis (Jindal, 1999). In pauci-immune RPGN the initial symptoms 
are non-specific; often fatigue, fever, night sweats and artheralgias are first clinical 
manifestations (Jindal, 1999). 
2. Histopathology characteristics of RPGN and laboratory findings 
Variable clinical manifestations and non-specific histologic changes complicate diagnosis 
and classification of vasculitis .To confirm the diagnosis light microscopy and immuno - 
fluorescence examinations of kidney biopsy shouldbe accompanied by appropriate serologic 
tests, includingANCA (Vizjak et al., 2003). 
2.1 Light microscopy findings 
Histopathologically, RPGN is characterized by avasculitis which involves glomerular 
capillaries, and results in formation of cellular crescents within most glomeruli (Hricik et al., 
1998). The hallmark histologic lesions are crescents; a morphologic expression of severe 
glomerular injury. In severe glomerular injury rupture of the glomerular capillaries allows 
inflammatory mediators to spill into Bowman's space, resulting in epithelial cell proliferation 
and invasion of monocyte and macrophage to Bowman's space (Couser, 1988; Jennette & Falk, 
1998; Jennette &Thomas, 2001). Crescents are divided into cellular, fibro cellular or fibrous 
types. Halmarks of irreversible glomerular or tubulointerstitial injuries are glomerular 
sclerosis, fibrous or fibro cellular crescents, and interstitial fibrosis.The lesions usually are seen 
in various stages of activity or resolution.Necrotizing inflammation in small cortical arteries is 
reported in 10   % of biopsy specimens .Inflammation of medullary vasa rectae with papillary 
necrosis is another finding that may be found(Lionakiet al., 2007). 
In acute pauci -immune glomerulonephritis(RPGN type III  ) fibrinoid necrosis accompanies 
crescents. These lesions occur at the same frequency irrespective of the presence or absence 
of associated vasculitis (DAgati et al., 1986). Acute lesions range from focal segmental 
fibrinoid necrosis affecting less than 10 %of glomeruli to severe diffuse necrotizing and 
crescentic glomerulonephritis that may injure all glomeruli.Periglomerular granulomatous 
inflammation may occur, but is not specific for pauci -immune glomerulonephritis 
(Lionakiet al., 2007). 
3. Histopathology characteristics on immunoflurecent microscopy 
Anti-GBM glomerulonephritis characterized by linear staining for IgG and usually C3 along 
the glomerular capillary. Immune complex-mediated glomerulonephritis, which is found in 
severe forms of various types of glomerulonephritis such as PSGN, IgA nephropathy, and 
lupus nephritis, characterized by granular glomerular staining for one or more immuno- 
globulins and/or complement components, and pauci-immune glomerulonephritis 
characterized by mild or absent glomerular tuft staining for immunoglobulins and/or 
complement (Rutgerset al., 2004  .)  
Anti-neutrophil cytoplasmic antibodies(ANCAs) associated glomerulonephritis are usually 
pauci immune; however, immunofluorescence microscopy often reveals a low level of 
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staining (less than +2, in the 0–4 scale (Harriset al., 1998). Figure 1 presents histologic 
findings in light and immunoflurecent microscopy. 
3.1 Electron microscopy findings 
On electron microscopy examination absence of electron-dense immune complex deposits 
(type I RPGN), multiple electron-dense deposits (type II RPGN), and few or no electron -
dense deposits (typeIII RPGN  ) are main findings (figure 2)(Haas, M.&Eustace, 2004). 
 
 
 
 
Fig. 1. Histopathologic findings in light and immunoflurecent microscopy (Lionakiet al., 2007) 
a/left; light microscopic demonstration of ANCA -associated necrotizing GN (with a crescent), 
arrows; (alveolar capillaritis with intra -alveolar hemorrhage); arrow; middle (and pulmonary 
necrotizing granulomatous inflammation with a multinucleated giant cell) arrow; right 
b/middle; Immunofluorescence microscopy can separate crescentic glomerulonephritis into anti -
GBM with linear IgG staining, ( left) immune complex with granular staining, (right); or pauci -
immune categories with little or no immunoglobulin staining  
4. Anti-neutrophil cytoplasmic and anti-GBM antibodies 
Anti -neutrophil cytoplasmic antibodies(ANCAs )are characteristic markers of small vessel 
vasculitides; Wegener’sgranulomatosis(WG), Microscopic polyangiitis(MPA), Churg -Strauss 
Syndrome(CSS), and idiopathic pauci -immune necrotizing glomerulonephritis for them the 
term ANCA associated vasculitides(AAV) has long being used(Jennette et al., 1989). 
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Fig. 2. Electron microscopy findings (Haas, M. &Eustace, 2004) 
C: Electron microscopy showing multiple sub-epithelial electron-dense deposits, some 
appearing partially resorbed, with extension of the glomerular basement membrane (GBM) 
around the deposits (uranyl acetate and lead citrate stain, original magnification ×6300)  
F: Electron microscopy showing a large subepithelial deposit in a “notch” area (arrow), as 
well as mesangial deposits (uranylacetate and lead citrate stain, original 
magnification×3800). 
The standard approach for detection of ANCA is indirect immunofluorescence (IIF) 
technique followed by antigen-specific quantitative assays .Myeloperoxidase (MPO) and 
proteinase3 (PR3) are major ANCA antigens (Falk .&Jennette, 1988; Goldschmeding et al., 
1989; Niles et al., 1989). 
In patients with RPGN, there are two major sub classes of ANCA, namely perinuclear  
(p - ANCA) and cytoplasmic (c - ANCA) (Guillevinet al., 1999  .) The main epitope of p -ANCA 
is myeloperoxidase(MPO), and that of c-ANCA is proteinase-3 (PR3) (Asarodet al., 2000). 
MPO-ANCAis a useful serum marker for MPA and idiopathic pauci -immune crescentic GN, 
and PR3-ANCA is regarded as a serum marker for Wegener’s granulomatosis and MPA  
(Asarodet al., 2000). Majority (approximately80- 85%) of cases of pauci-immune crescentic 
glomerulonephritis are ANCA positive(Haueret al., 2002;Jennette, 2003). Greater than 95% 
of cytoplasmic ANCA are PR3-ANCA and >95 %of perinuclear ANCA are MPO -ANCA 
(Lionakiet al., 2007). The c and p-ANCAs are mostly directed against the azurophilic 
granule proteins proteinase 3 (PR3)and myeloperoxidase (MPO), respectively .Detection of c 
and especially p-ANCAs are not equivalent to the presence of PR3-and MPO-ANCA. It is 
recommended to detect ANCA by an antigen-specific ELISA (Savigeet al., 2000; Cohen 
Tervaert et al., 1991). 
Anti-GBM antibodies which are directed to the non-collagenous part ofthe α 3 chain of type 
IV collagen, can also be evaluated byboth IIF and ELISA(Rutgerset al., 2004) .The ANCA -
GBM dot-blot is a qualitative assay that uses nitrocellulose strips on which purified antigens 
are blotted at preset spots .MPO and PR3 antigens that are used in these tests are produced 
from human leukocytes .The GBM-ANCA dot-blot assay has been revealed reactivities that 
had not been detected by ELISA(Table 1) (Rutgers et al., 2004). 
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Table 1. Characteristics of the GBM-ANCA Dot-Blot Assay (Rutgerset al., 2004) 
5. RPGN, Pulmonary–renal syndrome (PRS), and ANCA-associated vasculitis 
(AAVs) 
The ANCA-associated vasculitis(WG, MPA, and CSS) are a group of rare autoimmune 
conditions characterized by the development of necrotizing vasculitis .They share a number 
of clinical features and are therefore treated using similar treatment protocols. 
The AAVs are rare with an annual incidence of 20/million in Europe, with WG as the most 
common and CSS the least frequent (Ntatsaki et al., 2010).In far-east, MPA is more common 
than WG .It's thought that they arise from interaction between an environmental factor and 
a genetically predisposing agent(Ntatsaki et al., 2011). 
Pulmonary–renal syndrome (PRS) is defined as combination of diffuse alveolar hemorrhage 
(DAH) and glomerulonephritis(Savageet al., 1997;Seo& Stone, 2004;Jennette& Falk, 2003). 
This syndrome is caused by different diseases, including various forms of primary systemic 
vasculitis especially WG and MPA, ANCA-associated systemic vasculitis(AAV), Good 
pasture's syndrome, SLE, and infection-associated or drug induced glomerulonephritis 
(Westmanm et al., 1997;Brusselle, 2007). 
Immunologic injuries or non-immunologic mechanisms are involved in pathogenesis of 
PRS .Immunologic mechanisms such as production of anti-GBM antibodies, ANCA, 
immune complexes mediated injuries and non-immunologic mechanisms such as 
thrombotic microangiopathy(Rondeauet al., 1989 ) have been suggested .Pulmonary 
involvement in the majority of cases is the result of small-vessel vasculitis that involves 
arterioles, venules and alveolar capillaries (necrotic pulmonary capillaritis). These lesions 
are clinically expressed with DAH(Levy. &Winearls, 1994). In the majority of cases the 
underlying renal pathology is a form of focal proliferative glomerulonephritis  (Jayne et al., 
2000), with fibrinoid necrosis, as well as micro vascular thrombi, and extensive crescent 
formation accompanies glomerular tuft disease (Walters et al., 2010). 
According to results of ANCA pulmonary renal syndrome can be categorized into two sub -
groups: 
1. ANCA-positive Pulmonary–renal syndrome 
2. ANCA-negative Pulmonary–renal syndrome 
Circulating ANCAs are detected in the majority of pulmonary–renal syndromes( The 
Wegener's Granulomatosis Etanercept Trial [WGET] Research Group2005; Dickersinet al., 
1994.)Three major systemic vasculitis syndromes are associated with positive ANCAs 
consists of Wegener’s granulomatosis, microscopic polyangiitis and Churg–Strauss 
syndrome (The Wegener's Granulomatosis Etanercept Trial[ WGET]Research Group, 2005), 
and idiopathic pulmonary–renal syndrome(Bolton&turgill, 1989). 
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Majority of cases of pulmonary-renal syndromes are related to ANCA associated vasculitis 
(Brusselle, 2007).Pulmonary–renal syndrome in ANCA-negative systemic vasculitis is very 
rare and has been reported in Behçet’s disease, HSP, IgA nephropathy and in mixed cryo  –
globulinaemia and rarely in thrombotic thrombocytopenic purpura(TTP)(Naseri & 
Zabolinejad, 2008). 
ANCA-positive Pulmonary–renal syndrome :More than 80 %of patients with necrotizing 
pauci immune small -vessel vasculitis have circulating ANCA (Jennette .&Falk, 1997). The 
main clinicopathological expressions of AAV are WG, MPA, CSS and renal -limited 
vasculitis (RLV). The highest incidence is for WG in northern Europe (Haugebergm etal., 
1998; Watts et al., 2000, 2008; Laneet al., 2000; Reinhold-Keller et al., 2005), while the 
incidence of MPA/RLV is higher in Japan (Fujimotoet al., 2006). 
Wegener's granulomatosis (WG  ): Friedrich Wegener in 1939 was the firsti nvestigator to 
recognize a group of diseases characterized by extra vascular necrotizing granulomatous 
inflammation of the respiratory tract with vasculitis and/or glomerulonephritis (Schultz 
&Tozman, 1995). In 1983, Fauci et al reported details of 85 patients with Wegener's 
granulomatosis followed over a 21-year period. Their diagnosis was based on upper and 
lower respiratory tract complications, renal disease, and variable involvement of other 
organs with disseminated vasculitis .Tissue biopsies confirmed the characteristic clinical 
findings (Fauciet al., 1983).Pathologically Wegener’s granulomatosis was characterized by 
small-vessel necrotizing vasculitis and granulomatous inflammation involving mostly the 
upper and lower respiratory tracts and the kidneys (Sugimoto et al., 2007). 
Diffuse alveolar hemorrhage is the most serious complication in small-vessel vasculitis. 
Respiratory symptoms including cough and hemoptysis.CXR or chest CT-scan may reveal 
diffuse lung infiltrate.Clinical manifestations, pathologic and serologic findings play 
important role in the diagnosis of WG. 75 - 90 %of patients with active disease have PR3 -
ANCAs (Langford, 2005;, Ozaki, 2007). The role of PR3-ANCA in the pathogenesis of the 
disease is not clear, but in vitro evidence suggests that PR3 -ANCA can directly or indirectly 
damage endothelial cells (Preston et al., 2002).With the recognition of association between 
ANCAs and Wegener’sgranulomatosis, the concept of Wegener’s granulomatosishas been 
modified and recently a less restrictive definition has been proposed, termed ‘‘Wegener’s 
vasculitis.’’ This term includes ANCA-positive patients with clinical presentations of WG 
such as sinusitis, pulmonary infiltrates, nephritis, and documented necrotizing vasculitis, 
but without biopsy-proven granulomatousin flammation. Both classic Wegener’s 
granulomatosis and Wegner's vasculitis are different manifestations of the same disease 
process.The term ‘‘Wegener’ssyndrome "is a more generic term suggested by the working 
classification of ANCA-associated vasculitides(Tervaert, &Stegeman, 2003). 
Diagnostic criteria have been reported by the research group of intractable vasculitis, 
ministry ofHealth, Labor, and Welfare {MHLW  } of Japan for definite diagnosis of AAV 
including WG (Table 2) (Ozaki, 2007).Necrotizing granulomatous lesions commonly affect 
the ear, nose and throat (E), lung (L), and kidney(K).Systemic symptoms in WG are 
classified as the following : 
1. E Symptoms: nasal symptoms; purulent rhinorrhea, epistaxis, and a saddle nose, eye 
symptoms; ophthalmic pain, visual disturbance, and exophthalmia, ear symptoms; 
otalgia and otitis media, and throat symptoms; pharyngeal ulcer, hoarseness, and 
laryngeal obstruction. 
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2. lung (L)symptoms: bloody sputa, cough, and dyspnea  
3. Kidney(K)symptoms :hematuria, proteinuria, rapidly progressive renal failure, edema, 
and hypertension 
 
 
 
Table 2. Diagnostic criteria for Wegener’s granulomatosis (Ozaki, 2007) 
Biopsies of the nasal mucosa, lung, and kidney reveal necrotizing granulomatous vasculitis 
and necrotizing crescentic glomerulonephritis without immune deposits(Ozaki, 2007). WG 
with E, L, and K involvement is classified as the generalized form, while when there is no 
kidney involvement, E only, L only, or E  +L, the term of limited form is used. The 
therapeutic strategies are different for each forms (Ozaki, 2007). 
Microscopic polyangiitis (MPA) 
Renal and pulmonary symptoms are characteristic in MPA, and interstitial pneumonitis  
and pulmonary hemorrhage are common clinical features .MPO -ANCA is positive in  
50-75% of patients and biopsy of the lung and kidney reveals necrotizing vasculitis of 
arterioles, capillaries, and venules with few immune deposits necrotizing and crescentic 
GN (Ozaki; 2007). Granulomatous inflammation and asthma are not seen in MPA (Jennette 
&Falk, 1997).  
Table 3 presents diagnostic criteria for microscopic polyangiitis(Ozaki, 2007). 
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Allergic granulomatous angiitis (AGA) or Churg-Strauss syndrome(CSS) 
Churg and Strauss was firstly described allergic granulomatous angiitis(Churg, & Strauss, 
1951). The disease is characterized by presence of asthma, eosinophilia, and necrotizing 
granulomatous inflammation .Clinical manifestations of small-vessel vasculitis; palpable 
purpura of the lower extremities, mononeuritis multiplex, abdominal pain, and gastro  - 
intestinal bleeding develop several years after the onset of asthma.Positive MPO-ANCA are 
seen and skin biopsy shows necrotizing vasculitis of small vessels with massive eosinophilic 
infiltration and extravascular granulomatosis(Ozaki, 2007). Table 4 presents diagnostic 
criteria for CSS(Ozaki, 2007). 
 
 
Table 3. Diagnostic criteria for microscopic polyangiitis(Ozaki, 2007) 
SLE and AAV 
Systemic lupus erythromatosis is an autoimmune disorder .Variety of autoantibodies are 
present in SLE patients including ANCA which have been reported in 3 -69 %of 
cases(Molnaretal., 2002;Edgar et al., 1995; Pradhan et al., 2004).Some studies(Chinet al., 2000; 
Nishiyaet al., 1997) have reported p -ANCA in 37.3 -42 %of patients with lupus nephritis, 
mainly those who have diffuse proliferative GN(DPGN), and minority of patients without 
renal involvement. In Pradhan et al's study predominant ANCA pattern was p-ANCAwhile 
c-ANCApattern was not found in any patient(Pradhan et al., 2004).Their study revealed that 
ANCA can be used as a serological marker to differentiate vasculitides in lupus nephritis 
cases from SLE without nephritis. 
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Table 4. Diagnostic criteria for Churg-Strauss syndrome (Ozaki, 2007) 
 
 
 
 
Table 5. Correlation of organ involvement with ANCA serology and other autoantibodies in 
SLE patients(Pradhan et al., 2004) 
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Atypical or X-ANCA has been reported among SLE patients by Savige et al, This antibody 
showing specificities tocathepsin G and lactoferrin (Savige et al., 1996). Table 5 shows 
correlation of organ involvement with ANCA serology and other autoantibodies in SLE 
patients (Pradhan et al., 2004 ). 
6. Treatment of RPGN 
Untreated RPGN typically progresses to end -stage renal disease over a period of weeks to a 
few months. Early diagnosis and initiation of appropriate therapy is essential to minimize 
the degree of irreversible renal injuries. The therapy of most patients involves pulse methyl   -
prednisolone followed by daily oral prednisone, oral or intravenous (IV) cyclophosphamide, 
and in some cases plasmapheresis. Empiric therapywith IV methylprednisolone should be 
begun in patients with severe disease with adding of plasmapheresisespecially if the patient 
has hemoptysis (Appel et al., 2010), If a renal biopsy performs soon after initiating empiric 
therapy the histological abnormalities will not alter. 
6.1 Treatment of ANCA associated vasculitis (AAV) 
Pauci-immune crescentic glomerulonephritis is a severe form of glomerular inflammation, 
which if left untreated, usually progresses to end-stage renal failure in weeks or months, 
AAV is responsible for 80 %of cases(Sakaiet al., 2002).The evidence based studies for the 
management of the AAV is well established and the strategy of induction, consolidation and 
maintenance therapy is accepted. Guidelines have been designed by both the British Society 
for Rheumatology (Lapraiket al., 2007) and European league against rheumatism 
(Mukhtyaret al., 2009) on the management of the AAVs. The AAVs are conventionally 
treated with a strategy of remission induction followed by maintenance therapy using 
glucocorticoids combined with cyclophosphamide during induction and azathioprine 
(AZA) for maintenance (Ntatsaki et al., 2011). Current standard treatment is combination of 
cyclophosphamide and steroids, but the optimal doses, routes of administration, and 
duration of therapy remain poorly defined (Hotta, et al., 2005). As immunosuppressive 
therapies increases the risk of infection, therefore one of the most important aspect of 
successful treatment srategies should be sufficient attenuation of inflammation without 
serious immunosuppression which leading to life-threatening infection. 
Corticosteroids 
For the induction of remission corticosteroid regimen is recommended which includea daily 
intravenous pulse of methylprednisolone (15 mg /kg)for 3 days, followed by oral prednisone 
(1mg/kg/day) for 3 weeks, which then tapered progressively (Pagnouxet al., 2008). In pauci-
immuneRPGN and MPA usefulness of combination of methylprednisolone pulse therapy 
for 3 days, oral corticosteroid of 1mg/kg/day for 1 month, and cyclophos -phamide of  
2 mg  / kg/day for 6 to 12 months has been confirmed in several studies (Salama, et al., 2002;  
J indal, 1999; Hoffman, 1997; Guillevin et al., 1991). 
Cyclophosphamide(CYC) 
Different therapeutic agents have been used in treatment of AAV.Standard therapy for AAV 
is treatment with combination of cyclophosphamide and prednisolone(Pagnouxet al., 2008). 
After induction with daily oral or pulse intravenous cyclophosphamide therapy, relapse 
rates of 15  % at 12 months(Haubitzet al .,  1998), and 38  % at 30 months(Guillevinet al., 1997) 
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have been reported.In long-time follow-up 50 %of patients experience relapse within 5 years 
(Hoffman et al., 1992).Treatment with cyclophosphamide is effective, but also very toxic 
(Hoffmanet al., 1992).Repeated treatment with cyclophosphamide increases adverse effects. 
To avoid cyclophosphamide - related toxicity, alternative induction treatments are needed 
(Stassen et al., 2007). 
Mycophenolate mofetil (MMF)  : MMF is considered as a potent immuno suppressive drug 
with favorable side effects, so it has been considered as an alternative to cyclophosphamide 
treatment in patients with AAV (Stassen et al., 2007;Pesavento et al., 1999; Haidinger et al., 
2000; Joy et al., 2005;Koukoulaki, & Jayne, 2006). MMF is a drug which usually is well 
tolerated. In patients with auto-immune diseases such as SLE, MMF is effective in inducing 
remission with short-term efficacy which is comparable with cyclophosphamide (Chanet al., 
2000, 2005; Ong et al., 2005; Ginzler etal., 2005). Induction treatment with MMF and oral 
steroids consisted of oral MMF 1000 mg twice daily and oral prednisolone 1 mg/kg once 
daily (maximum 60 mg). If patients are still in remission after 1 year, MMF is tapered by  
500 mg every 3 months and Prednisolone is tapered after 6 weeks by 10 mg every2 weeks 
until a dose of 30 mg was reached, and by 5 mg every2 weeks until 10 mg. Next, the dose is 
reduced2.5 mg every month (Stassen et al., 2007). Stassen et al reported that combination of 
oral steroids and MMF induced complete and partial remission in 78% and 19 %of patients 
respectively(Stassen et al., 2007), Therefore they suggested oral steroids with MMF in 
patients with relapses of AAV intolerant to cyclophosphamide therapy.Bone marrow 
suppression is an uncommon side effect of MMF treatment which can result in anemia, 
leucocytopenia or thrombocytopenia in a number of patients .Fortunately this side effect 
responds to temporary dose reduction in nearly all patients( Stassen et al., 2007). 
Methotrexate(MTX) 
For remission maintenance in patients who are intolerant of AZA or relapse while taking it 
other alternative agents such as MTX or MMF have been recommended (Ntatsaki et al., 
2011). Methotrexate is an alternative drug for cyclophosphamide which is currently studied 
(De Grootet al., 2005; Sneller et al., 1995; Stoneet al., 1999). According to one randomized (De 
Groot et al., 2005) and two uncontrolled studies (Sneller et al., 1995; Stoneet al., 1999) MTX 
effectively induced remission in 90 %and 71–74 %of patients respectively, but relapses 
occurred more frequently than when cyclophosphamide was used (70%vs. 47%)(De Groot et 
al., 2005). MTX is excreted by kidney, therefore should be used with caution in those with 
renal impairment (Ntatsaki et al., 2011; M etzler et al., 2007). 
Groot et al conducted an unblended, randomized, controlled trial study todetermine 
whether MTX could replace treatment with cyclophosphamide and oral corticosteroids(De 
Grootet al., 2005).They found that MTX can replacecyclophosphamide for initial treatment 
of early AAV, but it was less effective for induction of remission in patients with extensive 
disease or those with pulmonaryinvolvement .In addition the relapse was more common in 
patients who treated with MTX than those who received cyclophosphamide.Patients were 
randomized to receive either MTX 7.5 mg/week increasing to 20 mg/week at 8 weeks or LEF 
loading dose 100 mg/day for 3 days, followed by20 mg /day until Week 4, then 30 mg/day 
for 2 years .Their study showed no differences in efficacy or safety between two treatments. 
Pagnoux et al(Pagnouxet al 2008)compared AZA with MTX in maintaining remission in WG 
and MPA patients who had achieved remission with intravenous pulse of cyclophos - 
phamide. They found no significant difference in adverse events and relapses rates either 
during the 12-month treatment phase or subsequent follow-up between two groups. 
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Intravenous immunoglobulins(IVIG) 
ANCAs can induce cytokine-primed neutrophils undergo degranulation and respiratory 
bursts during which they release toxic oxygen species and lytic enzymes (Falk et al., 1990). 
Anti-idiotype antibodies with inhibitory effects on ANCA in vitro have been found in a 
pooled human gamma globulin preparation (Pall et al., 1994.)Evidence showed that IVIG 
acts in different phases of theimmune response including neutralization of circulating 
pathogenic antibodies, Fc receptor modulation, blockade or suppression of antibody -
dependent cell toxicity, natural killer cell function, auto antibodyproduction and 
complement activation, and acceleration of neutrophil apoptosis (Kazatchkine & Kaver i, 
2001; Tsujimoto et al., 2002). 
Beneficial effect of high-dose intravenous immunoglobulin in ANCA–associated vasculitis 
has been approved by different studies (Ito-Iharaet al., 2006; Tuso et al., 1992; Jayneet al., 
1993; Richteret al., 1995). Ito et al evaluated IVIG monotherapy (400 mg/kg/day for 5 days)in 
AAV patients. Their study showed that IVIG decreased the leukocyte count, C- reactive 
protein level, Birmingham Vasculitis Activity Score and improved the systemic symptoms 
(Ito-Iharaet al., 2006). Other studies suggested that IVIG induces remission in 40–82% of 
patients (Richter et al., 1995; Jayne et al., 1991; Levy et al., 1999; Jayne et al., 2000). IVIG 
appears to have an important place in the management of ANCA-RPGN, but it's indications 
have not been determined. Because IVIG is an expensive drug additional studies on its cost-
effectiveness and rational introduction into clinical practice are needed(Hotta et al., 2005). 
Anti-B-cell therapy(Rituximab) 
Beneficial effects of Rituximab which is a monoclonal antibody against anti-CD20 have been 
reported in several case series(Gottenberg et al., 2005; Omdal et al., 2005; Speckset al., 2001), 
and uncontrolled studies( Eriksson, 2005; Keogh et al., 2005a, 2005b; Smith et al., 2006).The 
main problem of treatment with rituximab is that relapses commonly occurred after 6–9 
months(Keogh et al., 2005a, 2005b; Smith et al., 2006). 
Apheresis therapies 
Results of clinical trial of apheresis therapies, either plasmapheresis or cytapheresis in AAV 
are disappointing. These studies showed no benefit(Glöckner et al., 1988; Cole et al., 1992; 
Zäuneret al., 2002), benefits just in dialysis dependent patients(Pusey et al., 1991)or benefits 
on preserving the renal function (Furutaet al., 1998; Hasegawaet al., 2005). 
Pusey et al .Found that plasma exchange is of added benefit in dialysis -dependent patients 
because in patients who were initially dialysis-dependent, renal function was more likely to 
have recovered when treated with plasma exchange plus drugs rather than drugs alone 
(Pusey et al., 1991).Report from the European community group suggested that adding 
plasma exchange to immuno suppressive therapy was not beneficial if there was severe 
tubular atrophy and fewer than 33 %of the glomeruli were normal(De Lind van 
Wijngaarden et al., 1998). 
In contrast to AAV in anti-GBM RPGN, the beneficial effect of plasma exchange has been 
well established .It might be attributable to the direct role of anti-GBM antibody in the 
pathogenesis of anti-GBM antibody RPGN, while in AAV no direct role for ANCA have 
been established (Hotta et al., 2005). The main advantage of Apheresis therapies is that no 
severe infectious episodes have been noted (Nagaseet al., 1998; Sawadaet al., 2003). Japan 
nation wide survey of RPGN (Yamagataet al., 2004) recommends cytapheresis in patients 
with aggressive forms of RPGN (rapid deterioration of renal function like the PR3-ANCA-
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associated RPGN, or pulmonary renal syndrome complicated by severe inflammation, or 
relapses with high MPO-ANCA titer). 
Anti-TNF-alpha 
 Insights into the role of Th1 cytokines in the pathogenesis of WG have led to trial therapies 
with antagonists of tumor necrosis factor -alpha (TNFα)and inhibitors of monocyte function, 
such as interleukin -10(Kamesh et al., 2002) .Etanercept  ( Enbrel ;soluble receptors), infliximab 
(Remicade;human -mouse chimeric antibody against TNF), and adalimumab (Humila; human 
anti -TNF antibody)are biological antagonists of TNF(Ozaki, 2007).Etanercept have been 
reported ineffective in maintaining remission and a higher rate of malignancy have been noted 
in patients who have received the drug (Wegener's granulomatosis etanercept trial [WGET] 
research group, 2005).In an open label study, infliximab was added to standard immuno 
suppressive therapy in 16 patients with acute AAV at first presentation or relapse and in 16 
with persistent disease despite multiple immuno suppressive regimens, 88% of patients 
achieved remission within a mean of 6.4 weeks(Boothet al., 2004) . 
Anti-T cell antibodies :Different studies have been reported that active systemic vasculitis 
is mediated in part by T cell-induced injury .This finding has led to the evaluation of anti-T 
cell antibodies in patients with Wegener's granulomatosis who are resistant to cytotoxic 
therapy (Lockwoodet al., 1993; Hagenet al., 1995; Schmittet al., 2004). 
In one study, the administration of a combination of two humanized monoclonal antibodies 
led to long-lasting remission in four patients with different forms of refractory vasculitis  
( Lockwoodet al., 1993).In other study 15 patients with refractory disease received anti-
thymocyte globulin(ATG)which resulted in a partial or complete remission in 9 and 4 
patients, respectively (Schmittet al., 2004).The role of these experimental therapies remains 
to be determined. 
Intravenous azathioprine  
High dose intravenous azathioprine has been tested for treating a variety of immune-
mediated diseases .In one report, four patients with WG who had not responded to oral 
cyclophosphamide were treated with monthly infusions of azathioprine) (Benensonetal., 
2005).Two reached remission of disease, one of whom developed renal involvement during 
relapse, which responded to retreatment. 
15-Deoxyspergualin  
15 -deoxyspergualin (gusperimus), a drug with anti -proliferative effect on antigen -
stimulated B cells, has been evaluated in a small number of patients who didn't respond 
to cyclophosphamide or had contraindications to the use of cyclophosphamide .The 
administration of 15 -deoxyspergual in 20 patients resulted in complete or partial 
remission in six and eight respectively(Bircket al., 2003).All patient experienced transient 
leucopenia with each treatment cycle. In another study seven patients treated with 15 -
deoxyspergualin and glucocorticoids, all reached complete or partial remission .The main 
problem was that to maintain remission prolonged treatment up to 4 years was 
required(Schmittet al., 2005).In addition serial monitoring of white blood count is 
required to avoid excessive leucopenia.  
Radiation therapy  
Radiation therapy has been evaluated in patients with WG and air way involvement (
Eagletonet al., 1979; Neviani et al., 2002).The use of ionizing radiation for non-malignant 
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disease is controversial .Current data do not support its use in systemic disorder like 
Wegener's granulomatosis (Stone et al., 2010). 
Stem cell transplantation: High-dose, myeloablative chemotherapy with stem cell 
transplantation has been used for the treatment of refractory severe vasculitis. There are few 
case reports of successful treatment in patients with WG (Kötteret al., 2005). More studies 
are required to determine the role of stem cell transplantation in the management of 
resistant AAV. 
Prophylaxis against Pneumocystis carinii pneumonia(PCP) 
Opportunistic infections especially Pneumocystis carinii pneumonia are potentially fatal 
complications of immuno suppressive therapy in RPGN and AAV .The estimated incidence 
of PCP is approximately 6 percent(Ognibeneet al., 1995).Different approaches to prophylaxis 
against PCP infection during initial immunosuppressive therapy have been suggested: 
trimethoprim-sulfamethoxazole one single strength (80 mg/400 mg)tablet daily or one 
double strength tablet (160 mg/800 mg)three times per week or Atovaquone in patients who 
are allergic to sulfonamides or do not tolerate trimethoprim-sulfamethoxazole.During 
treatment with methotrexate and glucocorticoids, the addition of trimethoprim -
sulfamethoxazole increases the risk of pancytopenia, therefore Atovaquone is suggested for 
prophylaxis in such patients..It has been recommended to continue PCP prophylaxis in 
maintenance immuno suppressive therapy phase until the CD4-positive T cell count exceeds 
300/microL(Mansharamaniet al., 2000).patients who have received trimethoprim-
sulfamethoxazole for prophylaxis during induction, should continue the prophylaxis when 
azathioprine is used and switch to atovaquone when methotrexate is replaced for 
maintenance therapy. 
Some patients have low CD4 -positive T cell counts for prolonged periods after the cessation 
of cyclophosphamide and require prolonged PCP prophylaxis; in addition glucocorticoids 
should be tapered to the lowest possible dose .If patients develop neutropenia when receive 
prophylaxis, the drug should be switched to atovaquone (Stoneet al., 2010). 
Management of RPGN and AAV in pregnancy: As with active disease in non-pregnant 
patients, prednisone alone is relatively ineffective, and to induce remission combined 
therapy with cyclophosphamide is needed.The major challenges of treatment during 
pregnancy are potentially serious adverse effects which can occur with both MMF and 
cyclophosphamide. In addition, insufficient data about the safety of rituximab is available. 
High risk of skeletal and palatal defects, as well as malformations of the limbs and eyes has 
been noted in case of fetal cyclophosphamide exposure during the first trimester.Although 
fetal risk is much smaller during the second and third trimesters, pancytopenia and 
impaired fetal growth can occur .MMF fetal exposure increases the risk of miscarriage and 
congenital malformation such as cleft lip and palate .As a result, some consider MMF to be 
contraindicated in pregnancy.The safer immuno suppressive drugs that have been effective 
in WG and MPA include glucocorticoids, azathioprine, cyclosporine and tacrolimus. 
Alternatives that could be considered include cyclophosphamide or rituximab in the second 
or third trimester once organogenesis is complete(Stoneet al., 2010). 
6.1.1 Prognosis of RPGN and ANCA associated vasculitis 
RPGN If left untreated typically progresses to end-stage renal disease over a period of 
weeks to a few months .Patients with fewer crescents may present slowly progressive 
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course(Baldwin et al., 1987) .Despite various immuno suppressive therapy protocols 
mortality of ANCA positive RPGN is still high, and the major cause of death is infectious 
complications(Booth et al., 2003; De Lind van Wijngaardenet al 1998).Outcome of AAV 
depends on patient 's age, degree of renal impairement at presentation and presence of 
pulmonary involvement. During the first 6 months of treatment mortality is very high as a 
result of aggressive course of the disease and toxic effects of early immuno suppressive 
treatments(Sakai et al 2002;Boothet al., 2003). Although the introduction of steroids and 
cyclophosphamide pulse therapy have improved the overall mortality of AAV, the 2-year 
mortality rate is still high ( 20   % in 2-year follow-up)(Booth et al., 2003;Hogan et al., 
1996;Falk et al 2000;Franssen et al 2000). Serum creatinine, dialysis dependency, and 
percentage of non-crescentic glomeruli at diagnosis have been considered as the best 
predictors of disease outcome(Bajema et al., 1999; Levy et al., 2001; Slotet alو.2003).The 
prognosis for patients with anti-GBM antibody disease is poor(Hirayama, et al., 2008), and 
renal survival and mortality rates of 20.9%and 23.3 % at 6 months after onset have been 
reported respectively. Early diagnosis and starting treatment without delay might improve 
the prognosis(Hirayama, et al., 2008.)A large nationwide survey of RPGN in Japan showed 
that mortality correlates with age, severity of renal dysfunction, presence of pulmonary 
involvement, and high C-reactive protein level( Sakaiet al., 2002). The mortality rate of 
Japanese patients was higher than in European or American patients because of the high 
incidence of lethal infection (Hotta et al., 2005). 
Japan Nationwide Survey of RPGN noted that 6 -month renal and patients' survival for PR3-
ANCA -associated RPGN were 88.2 %and 92.3% respectively, while for MPO -ANCA they were 
69.9 %and 74.2 %respectively(Yamagata et al., 2005).patients' survival is very low in MPA if 
the disease presents as pulmonary renalsyndrome (Gallagheret al., 2002 Lauque et al., 2000; 
Niles et al., 1996).Introduction of immuno suppressive agents considerably has improved the 
outcome of AAV over the past 30 years .WG and MPA if left untreated have a rapidly 
progressive and usually fatal course(Ntatsaki et al., 2011). Walton reported a mean survival of 
5 months in patients with WG, and mortality rate of 82 %  and 89 %in 1 and 2 year follow -up 
respectively (Walton, 1958).Standard treatments significantly have improved prognosis in WG 
and MPA, and some studies have reported 5 -year survival rates of 81 % for MPA and 87   % for 
WG  (Eriksson et al., 2009).in European Vasculitis Study, there was 11.1 %mortality at 1 year  (
Littleet al., 2010.)High age at presentation, severe renal involvement (high serum 
creatininelevel at presentation), pulmonary involvement, high ESR and high scores of disease 
activity and damage were poor prognostic factors (Holle et al., 2011). 
Suzuki et al 's study confirmed that ANCA-associated vasculitis is the most serious 
etiologies of  RPGN( Suzukiet al., 2010).In nationwide survey byYamagata and Koyama 
(Koyamaet al., 2009; Yamagata et al., 2005), and Suzuki's study main causes of patients' 
death were infectious complications, including DIC which was mainly linked to pneumonia 
by opportunistic pathogens( Pneumocystis carinii, Candida albicans, and cytomegalovirus). 
Researchers hope they will find new immuno suppressive drugs with highest efficacy, 
lowest side effects and high safety during pregnancy to improve patients' survival and 
quality of life .It's a dream that undoubetly will be achieved in next years.  
7. Conclusion 
RPGN is a nephrology emergency which needs special attention.If the disease left untreated 
typically progresses to end-stage renal disease over a period of weeks to a few 
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months.When there is a strong clinical suspecsion special immuno suppressive treatment 
should be started as soon as possible (preferably after kidney biopsy) .Despite various 
immuno suppressive therapy protocols mortality of ANCA positive RPGN patients is still 
high, also prognosis of anti-GBM antibody disease is poor.acctually treatment of RPGN and 
AAV are serious challenges in nephrology medicine which needs more clinical trial studies 
in larger groups of patients. 
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